Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...

Passage Bio (PASG) announced new interim results from the first six patients in its Phase 1/2 study for PBGM01 targeted at GM1 Gangliosidosis ((GM1)), Read full story here.

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on March 4, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

Find the latest Insider Activity data for Passage Bio, Inc. Common Stock (PASG) at Nasdaq.com.

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio (NASDAQ:PASG) just reported results for the first quarter of 2024. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -36 cents. The ...